Replies to post #181718 on Biotech Values

[DewDiligence]

MabVax* collaborates with MSKCC/Juno in CAR-T:

http://finance.yahoo.com/news/mabvax-therapeutics-enters-agreements-memorial-130000663.html

Under the agreements, MabVax will supply unique targeting sequences from the fully-human antibodies to MSK. Pursuant to the agreement with MSK, researchers at MSK will conduct the early stage research and development of Chimeric Antigen Receptor (CAR) T-cell therapeutics using the MabVax antibody sequences and then test them both in vitro and in animal models with the objective of producing anti-cancer therapeutics targeting certain solid tumors.

MabVax and Juno entered into an exclusive option agreement giving Juno the right to negotiate a license agreement for exclusive rights to any CAR T-cell therapeutic products using the antibody sequences provided to MSKCC.

No financial terms are disclosed.

*MabVax is the result of a reverse merger with TELK; the ticker symbol will soon change to MBVX (#msg-106074587).